Background: The presence of genetic changes is a hallmark of chronic lymphocytic leukemia (CLL). The most common cytogenetic abnormalities with independent prognostic significance in CLL are 13q14, ATM and TP53 deletions and trisomy 12. However, CLL displays a great genetic and biological heterogeneity. The aim of this study was to analyze the genomic imbalances in CLL cytogenetic subsets from both genomic and gene expression perspectives to identify new recurrent alterations.
introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is characterized by a highly variable clinical course with survival times ranging from months to decades despite a remarkable phenotypic homogeneity [1, 2] . This clinical heterogeneity reflects its biological diversity [3] . Our understanding of the biology of CLL has helped to identify several markers of prognostic significance, delineating CLL into several distinct diseases. These markers include cytogenetic abnormalities, the mutational status of the immunoglobulin heavy chain variable (IGHV) and ZAP-70, CD38 and CD49d expression [2, [4] [5] [6] . Conventional cytogenetic analyses have revealed chromosomal aberrations in 40%-50% of patients, but detection of abnormalities is limited by the low mitotic activity of CLL cells. By contrast, interphase FISH (iFISH) has identified chromosomal changes in ∼80% of patients with CLL, the presence of specific chromosomal abnormalities being a prognostic indicator of disease progression and survival [2, 7] . Thus, half of the CLL patients carry deletions of 13q, which is correlated with an indolent disease course in patients with this abnormality as their sole aberration. In contrast, deletions of 11q and 17p (which cover the ATM and TP53 genes, respectively) have a poorer outcome. Furthermore, trisomy 12 is related to an intermediate prognosis, whereas deletion of 6q has been identified as a recurrent CLL progression marker [8] . In addition, great genomic complexity has been associated with worse survival and is also closely related to markers of poor prognosis [9] [10] [11] .
Considering the great heterogeneity of CLL from both genetic and prognostic points of view, microarray technology is a powerful tool for the analysis of genetic alterations in CLL. Thus, comparative genomic hybridization using high-density arrays, array comparative genomic hybridization (aCGH), allows high-resolution genome-wide scan for detection of copy number alterations in a single hybridization and aCGH using bacterial artificial chromosome (BAC) clones has been widely applied in the analysis of hematological malignancies [12] [13] [14] [15] . Regarding oligonucleotide microarrays, the study of the gene expression profile (GEP) in CLL has given us insights into the molecular mechanisms involved in its pathogenesis by analyzing the impact of genomic aberrations on the expression of genes located on the corresponding loci [16] [17] [18] .
Although the application of microarray technology in CLL has provided additional knowledge of the known recurrent aberrations as well as enabling novel aberrations, such as gain of 2p and deletion of 22q to be identified [19] [20] [21] [22] [23] , to date, few studies have investigated genomic aberrations specifically in relation to CLL cytogenetic subsets. Therefore, the aim of this study was not only to screen and identify new genomic events in CLL patients but also to compare the prevalence of these genomic aberrations in cytogenetic CLL subsets. Furthermore, our data revealed an association between altered transcription levels and genomic imbalances in the genetic subsets of CLL, indicating that gene dosage might have pathogenic effects in CLL and delineate a new gained region, on 20q13, in CLL patients.
methods
patients Peripheral blood samples from 67 patients with CLL were analyzed. The diagnoses were confirmed by standardized clinical, morphological and immunological data according to the World Health Organization classification and the criteria of the Working Group of the National Cancer Institute [24] . FISH studies and IGH mutational status were determined in all patients. The study protocol was approved by the local ethical committees and prior written informed consent was obtained from the patients. All patients were untreated and most of them were studied at the moment of diagnosis ( Table 1 ). The main characteristics of the 67 CLL patients included in the study are reported in Table 2 .
FISH analysis
Interphase FISH was carried on all the samples using commercially available probes for the following regions: 13q14, 12q13, 11q22/ATM, 17p13/TP53 and 14q32/IGH (Abbott Co., Downers Grove, IL) using the previously described methods [25] .
To confirm the gains and losses assessed by aCGH, FISH analysis was done using Vysis LSI ZNF217, the commercially available probe for 20q13.2 (Abbott Co.) and the BAC clones dJ1028D15-dJ781B1, mapping to 20q13.12, as previously described [25] . The clones were located in the same region of gain as detected by aCGH and were selected from the aCGH BAC clone library (Wellcome Trust Sanger Institute), whereas the commercial probe was located in 20q13.2 (breast tumor amplicon). DNA from the BAC clones was isolated, labeled and hybridized, as previously described [26] . The changes were validated in fixed cells from the same diagnostic samples as used for aCGH (n = 20).
FISH analysis was carried out on 400 interphase cells using standard fluorescent microscopy.
mutation status of IGVH genes
IGVH genes were amplified and sequenced according to the ERIC recommendations on IGHV gene mutational status analysis in CLL [27] . Table 1 . Status of disease in the total series (n = 67) and in + 20q CLL patients (n = 13) CLL patients (n = 67) + 20q CLL patients (n = 13) 
GEP analysis
RNA isolation, labeling and microarray hybridization were carried out, as previously reported [28] . The GEP was analyzed in all cases with Human Genome U133A microarray (Affymetrix, Santa Clara, CA). Data analysis is available as supplementary material (available at Annals of Oncology online).
comparative analysis of CGH and expression arrays
In order to achieve a comparative analysis of the copy number changes, from the CGH arrays, and the gene changes, from the expression arrays, for the same patients, we select the patients who showed significant gains in the aCGH data and their corresponding expression data. We normalized the expression dataset using the R package GeneMapper [29] that allows an accurate assignment to ENSEMBL genes (instead to Affymetrix probesets) including their location in the genome. Following this, we selected the three regions in chromosome 20q where the gains detected by aCGH were significative. For such regions, we calculate, in the corresponding samples, the mean and median expression signal based on the genes included. On these expression numbers, we carried out a statistical one-tail t-test (using R) to check if there was a significant correlation between the aCGH gain observed in the 20q regions and the overexpression of the genes included in such regions.
statistical analysis
Two-tailed Chi-square and Fisher's exact tests were used to analyze the associations between variables. For all tests, values of P < 0.05 were considered to indicate statistical significance. The calculations were carried out using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL).
results

FISH and mutational status
FISH analyses revealed that 25 of the 67 cases analyzed (37%) carried the 13q14 deletion and that this was the only abnormality in 20 patients (30%). Overall, the 11q22.3 and 17p13.1 deletions were present in 5 (7%) and 6 (9%) patients, respectively, while trisomy 12 was present in 11 (16%) and t (14q32) in 9 (13%) patients. The remaining 21 (31%) patients did not show aberrations by FISH. To better characterize the 20q13.12 gain, FISH analysis was also carried out in a validation series of 58 patients: 17% patients showed this alteration in ≥4.5% cells (ranging from 4.5% to 12%). In relation to mutational status, 49% of cases had unmutated IgVH gene.
aCGH showed recurrent genomic imbalances in CLL
Fifty of 67 patients (75%) displayed genomic changes with aCGH. In addition to the regions detected by FISH abnormalities, aCGH enabled the presence of novel recurrent genomic imbalances to be demonstrated. In order to rule out previously described single nucleotide polymorphisms, the minimal regions of overlap for all the recurrent lesions were Figure 1 . Most of these cases (75%) were studied at the time of diagnosis (Table 1) . Changes detected in diagnostic and progression groups are shown in Table 4 .
genomic abnormalities in the cytogenetic subgroups of CLL (Table 5 ). The analysis of the relationship between the recurrent abnormalities revealed by FISH and the presence of novel chromosomal imbalances detected by aCGH showed a significant association between the loss of 13q and the loss of 5q13.3-q14.1 and 5q31.1 (P < 0.05). No other additional abnormalities were observed in any of the cytogenetic subgroups.
In order to assess the genomic complexity in the cytogenetic CLL subsets, a comparison between the number of genetic changes ascertained by aCGH and the FISH CLL subgroup was carried out. As the median of changes per patient was five (range 0-14), we defined two groups to analyze the number of changes with respect to the FISH categories: ≤5 (low genomic complexity) and >5 (high genomic complexity) (Table 6 ). Interestingly, an association between the presence of a large number of changes detected by aCGH and ATM deletion (P = 0.026) by FISH was observed. The presence of gains on 20q12.13 (P = 0.002) was also associated with a high frequency of changes as revealed by aCGH (Table 6) .
oligonucleotide and FISH studies validated the changes observed by aCGH
Oligonucleotide aCGH was carried out in 35 cases to confirm the BAC array results. Genomic patterns of gains and losses representative of the probe sizes (∼150 kb) were compared 
gene expression profile confirmed the dosage effect of aCGH changes
In order to assess the relevance of the genomic imbalances in gene expression, a gene expression profile study was carried out. For this purpose, we grouped the cases by aCGH findings. The group of patients displaying trisomy 12 showed deregulation of 89 genes when compared with the rest of patients. A total of 76 of the 89 genes were overexpressed in relation to the other patients and 56% of them were located on chromosome 12.
It should be noted that overexpression of the 52 genes located in 20q13.12 (Figure 1) , the 20q region gained by aCGH, was also observed (P = 0.01). Among these genes, we found well-known protein-coding cancer-related genes (supplemental Table S1 , available at Annals of Oncology online) such as PI3 (elafin), SLPI (secretory leukocyte peptidase inhibitor) and WFDC2 [whey acidic protein (WAP) fourdisulfide core domain 2], members of the WAP family; PIGT ( phosphatidylinosotol glycan anchor biosynthesis, class T), a component of the glycosylphosphatidylinositol (GPI) glycan transamidase complex; HNF4A (hepatocyte nuclear factor 4, alpha) and YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide), members of the SMAD and Ras signal transduction pathways, respectively. In addition, ADA (adenosine deaminase), a regulator of B-cell proliferation, overexpression was also present in CLL cases with gains on 20q.
Moreover, in patients with the 17p13 deletion, a significant proportion (83%) of the differentially underexpressed genes clustered in this region (P < 0.05). Among the downregulated genes were GPS2 (G protein pathway suppressor 2)/AMF1, SGSM2 (small G protein signaling modulator 2), DRG2 (developmentally regulated GTP-binding protein 2), SAT2 (spermidine/spermine N1-acetyltransferase family member 2) and C17orf49 (chromosome 17 open reading frame 49). This gene dosage effect was also observed in CLL patients showing 11q-. Thus, all the genes located in the minimal region of deletion observed with aCGH on 11q22.3-q23.2 (108518932-112964950 bp) were downregulated when compared with the rest of patients (P < 0.01).
discussion
The presence of cytogenetic abnormalities is a hallmark of CLL. Indeed, these abnormalities have been associated with the prognosis or progression of the disease and for this reason the genetic changes have been extensively studied in CLL [30, 31] . The present study integrates genomic and gene expression profile analyses in a cohort of 67 CLL patients. Overall, the results enable us to detect hitherto undescribed recurrent alterations in CLL, such as gains on chromosome 20 and confirm the dosage effect, not only for the common cytogenetic abnormalities but also for this new genetic abnormality.
The present study found genomic copy number changes in 75% of the CLL patients. Our findings are similar to those previously reported in this disease [19, 22, 23, 32] . Detection rates of genomic alterations involving loci known to be associated with CLL occurred at expected frequencies [33] and overall, correlation between FISH and aCGH was observed except in the 13q-subgroup. Both FISH and aCGH revealed that 13q-was an heterogeneous group in size of the deletion and percentage of cells displaying the abnormality. Interestingly, when aCGH failed to demonstrate the presence of 13q deletion, FISH data revealed that most of these cases had <30%. This could justify, at least in part, the lack of correlation between both the techniques. We also confirmed that deletions are more abundant than gains in CLL: deletions in chromosomes 5, 7, 11, 13, 17 and 18 and gains in chromosomes 1, 6, 10, 11, 12, 16, 17, 18 and 20 were present in this series. Regarding other recently reported alterations, we observed gain on 2p [34] in one case. Our study identifies a previously undescribed recurrent region of gain in CLL, located on 20q13 in 19% of CLL patients.
This frequency is similar to other well-characterized abnormalities in CLL ( + 12, 11q-and 17p-). It should be noted that gains in 20q were not associated with any other cytogenetic abnormality, although no patients with loss on 17p displayed 20q gains. The presence of 20q gains was not associated with mutational status either. Abnormalities of chromosome 20 are frequently observed aberrations in cancer [35] [36] [37] . In addition, the presence of gains on 20q has been associated with aggressive tumor behavior and poor clinical prognosis [38] . By contrast, deletions of the long arm of chromosome 20 are a common chromosomal abnormality associated with myeloid malignancies and are rarely seen in lymphoid malignancies [39] . A detailed analysis of 20q gains in cancer revealed that the size and location of the alteration are both variable. A region of gain at 20q13 was identified in CGH studies in human breast tumors [40] . The region has been analyzed at higher resolution, The gain on 20q13 in CLL could be relevant to the pathogenesis and evolution of CLL because 11 protein-coding cancer-related genes have been identified in this region (supplemental Table S1 , available at Annals of Oncology online). It should be noted that all of these genes were upregulated in the CLL patients showing 20q gains in comparison with the other CLL cases. Thus, PIGT, PI3, SLPI and WFDC2 could be potential candidate genes since they have been previously related to progression or tumor invasion. Phosphatidylinositol glycan (PIG) class T (PIG-T) is a component of the GPI transamidase complex and is amplified and overexpressed in human breast cancer cell lines and primary tumors [41] . Previous studies suggested that activation of the GPI transamidase complex could be a molecular mechanism underlying the progression of various human cancers [41, 42] . Interestingly, GIP-S, another GPI subunit, is located on 17p13.2, a region frequently deleted in cancer and in CLL. Therefore, further studies of these genes and their biological effects of all GPI transamidase complex subunits could be relevant in CLL. PI3, SLPI and WFDC2 are members of the WAP family, a group of genes coding for proteins with a WAP motif. All of them have been identified as molecular markers for cancer and are clustered on chromosome 20q12-13.1. These genes are amplified and upregulated in several cancers [43] . The expression levels of all these genes were significantly higher in CLL cases with gains on 20q. Therefore, we suggest that 20q13.12 overexpressed genes may also be important in the evolution of CLL and warrant detailed study.
The present study also revealed a gene dosage effect in other chromosomal regions. Thus, CLL patients with trisomy 12 overexpressed genes located on chromosome 12, while patients with losses on 17p underexpressed genes located on 17p, as previously reported [16] [17] [18] .
Gains in 20q13 in CLL did not occur as a single aberration because all CLL patients with gains in this region also had additional genetic changes. In fact, gains on 20q were associated with genomic complexity (Table 6 ). It is of note that genomic complexity has a significant impact on cancer prognosis and a number of studies have described the presence of several genomic changes as being predictors of disease progression and chemosensitivity in CLL [9, 44] . A significantly high level of genomic complexity in patients with loss on 11q was also observed. However, the CLL patients with losses on 17p did not have a large number of genomic alterations. This observation may indicate that the poor prognosis of patients with CLL exhibiting loss on 17p is unrelated to their genomic complexity [9] . The presence of a large number of genomic alterations in 20q13-gain patients suggest that this new genetic entity could be associated with a more advanced disease in CLL, as has been suggested in non-Hodgkin's lymphomas [45] . Genomic instability could therefore be another molecular feature of CLL progression, as has recently been suggested [46] . In order better to assess the clinical value of gain on 20q, a prospective study in a large series of CLL patients needs to be carried out.
Our results failed to demonstrate the presence of recurrent secondary genetic imbalances in the cytogenetic subgroups. In fact, only the group of patients with losses in 13q showed an association with losses in 5q13.3-q14.1 and 5q31. These changes had not been previously reported and could be examined further in subsequent studies.
In summary, our results demonstrated that submicroscopic 20q13.12 gains are common in CLL and confirmed that these gains result in an overexpression of the genes located on 20q13 [ Figure 1 , supplemental Table S1 (available at Annals of Oncology online)]. Furthermore, 20q gain is associated with great genomic complexity. These results suggest that the diversity of genomic aberrations in CLL is much greater than previously suggested. Further studies are needed to assess the prognostic significance of these alterations and how the genes located in these loci could contribute to the pathogenesis of CLL. 
